# Tenpoint Therapeutics

Tenpoint Therapeutics is an Asset Manager based in Seattle, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Seattle, United States
- **Region:** North America
- **Address:** Seattle, WA, United States
- **Assets under management:** Undisclosed
- **Website:** tenpointtherapeutics.com
- **LinkedIn:** https://www.linkedin.com/company/tenpointtherapeutics

## Regulatory record

- **Reports private funds:** No

## About

Discover how innovative eye treatments from Tenpoint Therapeutics™ may help restore lens clarity and rejuvenate vision in aging eyes.

## Sectors

- Digital Health
- Biotech & Pharmaceuticals
- Ophthalmology

## People

- Ben Bergo — President, Chief Business Officer
- Henric Bjarke — Chief Executive Officer
- Esther Cuno — Vice President of Human Resources
- Melissa Epperly — Chief Financial Officer
- Stephen S. Lane, MD — Chief Medical Officer
- Tim Grinstead — Chief Operating Officer
- Carol Kearney — Chief Commercial Officer
- Yemisi Corinaldi — Vice President of Regulatory Affairs
- David Guyer, MD — Chairman of the Board
- John de Koning, PhD — Director
- Eric D. Donnenfeld, MD — Director
- Carmine Circelli — Director
- Jim Mazzo — Director
- Alexander Pasteur — Director
- Graziano Seghezzi — Director
- Tracy M. Valorie — Director
- Zichao (Jason) Zhang — Director

## Questions

### Does Tenpoint Therapeutics operate more like a biotech startup or a fully integrated pharma company?

Tenpoint markets itself as an integrated eye-care company — it is building its own commercial team under Chief Commercial Officer Carol Kearney rather than seeking an approval-and-partner pathway. This ambition places it between a development-stage biotech and a specialty-pharma operating company, with the attendant capital requirements. No disclosed funding rounds or revenue yet confirm its balance-sheet capacity to launch at scale.

### What eye conditions beyond presbyopia does Tenpoint target?

The firm's pipeline includes programs for early cataract — aiming to restore lens clarity pharmacologically — and a cell-therapy program for geographic atrophy, the advanced form of dry age-related macular degeneration. Tenpoint frames these as a continuum of lens and retinal rejuvenation, though no clinical data or trial identifiers are publicly disclosed beyond the presbyopia NDA.

## Related profiles

- [United Utility Services](https://altss.com/profile/united-utility-services)
- [Bridgebank Capital](https://altss.com/profile/bridgebank-capital)

---

Last updated: 2026-07-06T00:38:58.288Z

Canonical page: https://altss.com/profile/visus-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology